Milestone Log Clause Samples

The Milestone Log clause establishes a formal record of key project milestones, tracking their completion and associated deliverables. Typically, this clause requires the parties to maintain and update a schedule or log that lists each milestone, its expected completion date, and any relevant documentation or approvals needed. By providing a clear framework for monitoring progress, the Milestone Log clause helps ensure accountability, facilitates project management, and reduces the risk of disputes over missed deadlines or incomplete work.
Milestone Log. Provide milestones for each budget period (or phase) of the project. Each milestone should include a title and planned completion date. Milestones should be quantitative (e.g., a date, a decision to be made, a key event) and show progress toward budget period and/or project goals. Milestones should also be important and few. Higher TRL projects (Demonstration and Deployment) typically have the most detailed milestone logs compared to lower TRL level projects (Research and Development). If applicable, milestones Note: The Milestone Status must present actual performance in comparison with the Milestone Log, and include: (a) The actual status and progress of the project,‌ (b) Specific progress made toward achieving the project's milestones, and, (c) Any proposed changes in the project's schedule required to complete milestones.
View SourceView Similar (2)
Milestone Log. Provide milestones for each budget period (or phase) of the project. Each milestone should include a title and planned completion date. Milestones should be quantitative and show progress toward budget period and/or project goals. [Note: During project performance, the Recipient will report the Milestone Status as part of the required quarterly Research Performance Progress Report (RPPR) as prescribed under Attachment b2, Reporting Requirements Checklist. The Milestone Status will present actual performance in comparison with Milestone Log, and include:
View SourceView Similar (2)
Milestone Log. Provide milestones for each budget period (or phase) of the project. Each milestone should include a title and planned completion date. Milestones should be quantitative (e.g., a date, a decision to be made, a key event) and show progress toward budget period and/or project goals. Milestones should also be important and few. Higher TRL projects (Demonstration and Deployment) typically have the most detailed milestone logs compared to lower TRL level projects (Research and Development). If applicable, milestones chosen should clearly reflect progress through various TRL stages.
View Source
Milestone Log. Provide milestones for each budget period (or phase) of the project. Each milestone should include a title and planned completion date. Milestones should be quantitative and show progress toward budget period and/or project goals. The following are examples of the type of milestones that should be included in the Project Management Plan. These should be tailored to meet the specific work tasks of the project (some may be deleted if not applicable): · Initial Simulation and Modeling Complete · Initial (Material, Component, or Process) Specifications Complete · Initial (Material, Component, or Process) Design Complete · Commercialization Plan Complete · Initial (Material, Component, or Process) Development & Testing Complete · (Material, Component, or Process) Downselection Complete · Test Cell (Material, Component, or Process) and Systems Demonstrations Initiated · Test Cell (Material, Component, or Process) and Systems Demonstrations Completed · Delivery of Technology or Material for Government Confirmatory Testing Completed (AOIs 4 and 5 only) · Systems Integration Design Complete · Vehicle Integration and Demonstration Initiated · Vehicle Integration and Demonstration 50% Completed · Vehicle Integration and Demonstration 100% Completed [Note: During project performance, the Recipient will report the Milestone Status as part of the required quarterly Progress Report as prescribed in the award document under Attachment 4, Reporting Requirements Checklist. The Milestone Status will present actual performance in comparison with Milestone Log, and include: (1) the actual status and progress of the project, (2) specific progress made toward achieving the project’s milestones, and, (3) any proposed changes in the project’s schedule required to complete milestones. ]
View Source

Related to Milestone Log

  • Milestone Event Milestone Payment [***] [***]

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Milestone Payment The first time Net Sales in the Territory in a Royalty Period exceed [***] [***]